DURABILITY of SARS-CoV-2 mRNA VACCINE IMMUNE RESPONSE in PLWH with ADVANCED DISEASE
Topics in Antiviral Medicine
; 30(1 SUPPL):109-110, 2022.
Article
in English
| EMBASE | ID: covidwho-1880108
ABSTRACT
Background:
Waning of vaccine protection against SARS-CoV-2 infection is currently a concern and durability of specific immunity after vaccination in PLWH is still unknown. The aim of this analysis was to evaluate persistence of immune response to mRNA vaccines in PLWH with advanced disease.Methods:
PLWH with a CD4 count ≤200/mm3 and/or previous AIDS, enrolled in a SARS-CoV-2 vaccination program at INMI hospital in Rome, Italy, were evaluated >90 days after 2nd dose of BNT162b2 or mRNA-1273 (time T1). Anti-RBD by CLIA, neutralizing antibody (nAb) titers by microneutralization assay (MNA90) and IFNγ production were assessed and response defined as having anti-RBD >7.1 BAU/mL, nAbs ≥110, IFNγ >12 pg/mL. Participants were stratified by CD4 count (severe immunodeficiency, SID, ≤200/mm3;minor immunodeficiency, MID, 201-500/mm3;no immunodeficiency, NID, >500/mm3). Waning of immune response was evaluated in a subgroup of responders for whom two values post 2nd dose were available. Paired t-test was used to test the overall decline. ANOVA and logistic regression analysis controlling for age, viral load, CD4 nadir and cancer were used for comparisons by CD4 groups.Results:
221 pts were included (SID=47;MID=98;NID=76);81% male;median age 55 yrs (IQR 49-60);median time from HIV diagnosis 7 yrs (3-15);74% previous AIDS diagnosis;median CD4 nadir 44/mm3 (16-122). All pts receiving ART, 87% with HIV-RNA<50 cp/mL. After a median of 145 (133-157) days after 2nd dose, a detectable anti-RBD response was still present in 83% of SID, 96% of MID and 98% of NID (P=0.0009);nAbs in 38% of SID, 78% of MID and 88% of NID (P<0.0001);IFNγ in 67% of SID, 90% of MID and 92% of NID (P=0.0002). Magnitude of residual immune response at T1 was significantly lower in SID (Figure 1a). By logistic regression, risk of nAbs undetectability was higher in SID (aOR 5.03;95% CI 1.22-20.81) and in MID (aOR 3.77;11.4-12.48) vs NID, while no evidence for a difference was found for anti-RBD and IFNγ. A significant decline of immune response was observed for all immune parameters [mean log2 (SD)-2.66 (1.08), p<0.001, for anti-RBD;-1.23 (1.26), p<0.001, for nAbs;and-0.51 (2.3), p=0.05, for IFNγ], regardless of CD4 groups (Figure 1b/c).Conclusion:
A high proportion of PLWH with advanced disease showed a lack of immune response after a median of 5 months from SARS-CoV-2 mRNA vaccination, suggesting an urgent need for a booster dose. A current CD4 ≤200/mm3 was associated with higher risk of vanishing of neutralizing activity.
CD4 antigen; elasomeran; endogenous compound; gamma interferon; messenger RNA; neutralizing antibody; RNA vaccine; tozinameran; acquired immune deficiency syndrome; adult; advanced cancer; analysis of variance; CD4 lymphocyte count; chemiluminescence immunoassay; conference abstract; controlled study; female; gene expression; human; Human immunodeficiency virus; immune deficiency; immune response; Italy; major clinical study; male; malignant neoplasm; middle aged; nonhuman; Severe acute respiratory syndrome coronavirus 2; vaccination; virus load
Search on Google
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Topics in Antiviral Medicine
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS